A medical technology company developing non-invasive cancer diagnostics, BARD1 Life Sciences Limited (ASX: BD1) has announced results that showed a significant cancer vaccine effect in malignant mesothelioma supporting further research to develop a potential BARD1 vaccine using an optimised vaccine strategy. The cancer vaccine study was carried out in collaboration with the Institute for Respiratory Health.
BARD1 previously reported encouraging initial results showing delayed tumour growth in a malignant mesothelioma mouse model, as reported in the Company Presentation released in November 2018. The results confirm a significant but moderate vaccine effect on tumour growth, survival and immune response using a 5-peptide BARD1 vaccine in the AB1 malignant mesothelioma mouse model.
The study concluded that the ‘naked’ 5-peptide BARD1 vaccine showed a significant but variable vaccine effect on tumour growth, survival and immune response in the malignant mesothelioma model using both prophylactic and therapeutic approaches. However, no significant vaccine effect was observed in the lung, colon or breast cancer models. These findings suggest that the 5-peptide BARD1 vaccine formulation and a dose selected in this study is unlikely to be optimal and therefore further studies are required to optimise the therapeutic effects of BARD1 vaccines on tumour growth in different tumour types.
BARD1 Executive Director and CSO Dr Irmgard Irminger-Finger said that the results were consistent with previous independent studies that showed that cancer-specific BARD1 epitopes were immunogenic and protect against tumour progression in a mouse model of colon cancer3 and subsequent research showed that a BARD1 DNA vaccine decreased tumour progression in a rat model of ovarian cancer4.
IRH Associate Professor Steven Mutsaers added that it was an exploratory research program that showed a small but significant immune response in the BARD1 vaccinated animals compared to the adjuvant controls using a crude vaccine formulation, which required further investigation to determine its biological importance.
On 25 January 2019, BD1 published its quarterly business update for the period ended 31 December 2018. The cash position of the company stood at $3.7m as of 31 December 2018. During the quarter new BARD1 completed the Breast Cancer Test: World-first BARD1-Breast cancer test which showed high accuracy for detection of breast cancer with 70% sensitivity and 88% specificity. Assay development program stated that the Feasibility phase was completed, and the development phase was underway. The New patent grant- Chinese divisional patent was granted, providing additional protection for BARD1-Lung. During the quarter, BARD1 LSL issued 165,732,775 New Shares at an issue price of $0.02 per share by way of a non-renounceable Entitlement Issue raising $3.315 million before costs. A total of 59,141,274 New Shares were issued to existing Shareholders who participated in the Entitlement Issue, with all BARD1 directors taking up some or all their rights. The remaining 106,591,501 Shortfall Shares were issued to sophisticated and professional investors.
The stock of the company is currently trading at A$0.019 (as at 15 February 2019, 3:11 pm AEST), down by 20.833% or 0.005 points.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.